IBEX Technologies

IBEX Technologies Inc is a biopharmaceutical company developing enzyme-based therapeutics for a variety of applications, particularly cardiovascular disease and diseases of genetic origin.In January 2007, IBEX entered into an agreement for the acquisition of all of the outstandingt shares of Garvinci, a private Canadian specialty pharmaceutical company with the Canadian distribution rights for a pipeline of arthritis and women's health products. The transaction, subject to regulatory approval was expected to close in April 2007,. In April 2007, Garvinci acquired rights to two arthritis device products for the Canadian market from TRB CHEMEDICA International. In April 2007, IBEX Technologies was to hold a special meeting of shareholders on, May 28, 2007, for the purpose of approving the acquisition. The acquirement had been conditionally approved by the Toronto Stock Exchange and IBEX's Board had unanimously recommended that shareholders vote in favour of the acquisition. At that